The relationship between hearing loss and PDE5 inhibitors is one of the least understood entries on the label of every erectile dysfunction medication on the market. Since 2007, the prescribing information for sildenafil, tadalafil, vardenafil and avanafil has carried a warning about sudden decrease or loss of hearing. Nearly two decades later, the warning remains, the mechanism remains unproven, and the absolute risk remains genuinely small — but the evidence base has grown enough to say something more precise than "it has been reported." This article summarizes what the published data actually establishes, what it does not, and what a man taking a PDE5 inhibitor should reasonably do with that information.
The Shared Microvasculature of the Cochlea and the Penis
The biological plausibility of a link begins with anatomy. The inner ear is supplied by the labyrinthine artery, a terminal vessel with effectively no collateral circulation. Like the cavernosal arteries of the penis, it is a small-calibre, end-organ supply whose function depends heavily on nitric oxide signaling and endothelial health. When a vascular bed has no backup route, a transient perfusion failure produces permanent injury rather than temporary dysfunction.
That architecture explains why cochlear and erectile tissue tend to fail under the same systemic conditions. Diabetes, hypertension, dyslipidaemia and smoking damage both. Phosphodiesterase type 5 is expressed in cochlear tissue as well as in the corpus cavernosum, which means a drug designed to raise cyclic GMP in penile smooth muscle is not pharmacologically silent in the ear. Whether that effect is protective, harmful, or clinically irrelevant at therapeutic doses is precisely the question the literature has struggled to settle.
What the Case-Level Evidence Shows
The most rigorous recent synthesis is a 2026 systematic review in International Archives of Otorhinolaryngology, which searched PubMed, Embase and Web of Science for reports of hearing loss in PDE5 inhibitor users [1]. From 190 abstracts, only six studies met inclusion criteria, together describing 54 patients aged 37 to 62. Sildenafil, vardenafil and tadalafil were the agents most commonly involved. Every patient had sensorineural hearing loss ranging from moderate to profound; four also reported tinnitus and three reported vertigo. One case involved bilateral hearing loss beginning fifteen days after starting sildenafil.
Two findings from that review deserve emphasis. First, corticosteroid therapy was the only treatment used across all cases, reflecting the standard approach to sudden sensorineural hearing loss rather than any PDE5-specific antidote. Second, among the seven patients with long-term follow-up after stopping the drug, four had no improvement at all, two recovered fully, and one recovered partially. The signal is rare, but when it occurs it is not reliably reversible.
Pharmacovigilance Data: Rare, but Consistently Reported
Case series cannot estimate risk. Pharmacovigilance databases cannot either, strictly speaking, but they do measure whether a signal appears more often than chance would predict. A disproportionality analysis of the FDA Adverse Event Reporting System covering the fourth quarter of 2003 through the second quarter of 2023 identified 1,438 reported cases of hearing impairment associated with the four PDE5 inhibitors [2]. The reporting odds ratio, proportional reporting ratio and information component were all statistically significant.
The severity distribution in that dataset is the part clinicians tend to find sobering. Disability rates across the four drugs ranged from 8.14% to 40%, initial or prolonged hospitalization from 6.21% to 10.24%, and required intervention from 3.31% to 9.45%. Patients averaged over 55 years of age and more than 70% were men. A 2026 FAERS analysis focused specifically on tadalafil reached a similar conclusion, confirming that ear and labyrinth disorders remain a detectable signal in contemporary real-world reporting [3].
These numbers describe the character of reported events, not their frequency in the treated population. Spontaneous reporting systems overrepresent serious outcomes and cannot supply a denominator. What they establish is that the events being reported are real, clinically significant, and have not disappeared with time or with newer agents.
Population Data and the Sildenafil-Specific Signal
The only population-based attempt to quantify the association comes from an analysis of 11,525 American men aged 40 and over in the Medical Expenditure Panel Survey [4]. Self-reported hearing impairment had an overall prevalence of 17.9%, while PDE5 inhibitor use stood at 2%. Men reporting hearing impairment were more likely to report use of any PDE5 inhibitor, with an odds ratio of 2.23 (95% CI 1.36–3.66).
Critically, that association was driven entirely by sildenafil (OR 2.05; 95% CI 1.23–3.43). Neither tadalafil (OR 1.40; 95% CI 0.49–4.04) nor vardenafil (OR 0.88; 95% CI 0.35–2.22) reached statistical significance. The author concluded that existing label warnings appeared justified, while stressing that a cross-sectional design cannot establish which came first. That caveat is not a formality. Men with vascular disease are more likely to develop both erectile dysfunction and age-related hearing loss, and they are also more likely to be prescribed a PDE5 inhibitor. Confounding by indication is the obvious alternative explanation, and no study to date has excluded it.
The Association Runs in Both Directions
Perhaps the most informative dataset is one that has nothing to do with drug exposure. A nationwide population-based cohort study in Taiwan followed men diagnosed with sudden sensorineural hearing loss and found a significantly increased subsequent risk of erectile dysfunction compared with matched controls [5]. These were men whose hearing loss preceded any erectile complaint.
That temporal ordering matters. If inner ear failure predicts later erectile dysfunction in men who were never exposed to a PDE5 inhibitor, then at least part of the observed overlap between the two conditions reflects a shared microvascular substrate rather than drug toxicity. Sudden hearing loss in a middle-aged man is, in this reading, a vascular event in a small end-artery — the same category of event that erectile dysfunction frequently signals years before a cardiac diagnosis. For a broader treatment of that idea, see our other articles on vascular health at /blog.
What This Means in Practice
The practical guidance that follows from this literature is narrow and worth stating plainly. Sudden hearing loss, with or without tinnitus or vertigo, is an otologic emergency. Treatment outcomes for sudden sensorineural hearing loss deteriorate sharply with delay, and the case data above show that recovery is far from guaranteed even with prompt corticosteroid therapy. Any man who experiences an abrupt change in hearing while taking a PDE5 inhibitor should stop the medication and seek same-day medical assessment rather than waiting to see whether it resolves.
Equally, the data do not support avoiding PDE5 inhibitors out of fear of this outcome. These are among the most widely prescribed drugs in the world, with a cumulative exposure measured in billions of doses, against a case literature of a few dozen well-documented events. The appropriate response is informed prescribing and attentive follow-up, not avoidance. Men with pre-existing hearing impairment, a history of sudden hearing loss, or significant vascular risk factors are the group for whom a physician-supervised treatment plan — including a baseline conversation about hearing — carries the most value.
Conclusion
The evidence linking hearing loss and PDE5 inhibitors is real but modest: a consistent pharmacovigilance signal, a small case literature with poor recovery rates, one cross-sectional association limited to sildenafil, and a cohort study suggesting the overlap partly reflects shared microvascular biology rather than drug effect. Clinical studies suggest the absolute risk is low. What the data does justify is prescribing within a medical relationship, where risk factors are reviewed before treatment begins and unusual symptoms are evaluated quickly rather than ignored.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. Our daily formulation, EPIQ CHEWS, combines low-dose tadalafil and vardenafil with vitamin D3 and K2 and is prescribed only after physician review of your medical history.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Pinkus P, Farsi S, Strickland WD, Tong L, Dornhoffer JL, Saadi RA. Sensorineural Hearing Loss and Phosphodiesterase-5 Inhibitors: A Systematic Review. International Archives of Otorhinolaryngology. 2026;30(3):1-8. doi:10.1055/s-0046-1820094
Zhang X, Xia L, Yang Q, Tang P. Phosphodiesterase type 5 inhibitors related hearing impairment: a real world study based on the FDA adverse event reporting system. Scientific Reports. 2024;14(1):9743. doi:10.1038/s41598-024-60493-w
Li J, Li K, Yang S, Chen Y, Ren P, Deng G, Lei L, Ma Q, Yang H, Deng L. Safety profile and signal detection of tadalafil: a real-world analysis based on the Food and Drug adverse event reporting system. Sexual Medicine. 2026;14(2):qfag014. doi:10.1093/sexmed/qfag014
McGwin G Jr. Phosphodiesterase type 5 inhibitor use and hearing impairment. Archives of Otolaryngology–Head & Neck Surgery. 2010;136(5):488-492. doi:10.1001/archoto.2010.51
Hsu HT, Chen JY, Weng SF, Huang KH, Lin YS. Increased risk of erectile dysfunction in patients with sudden sensorineural hearing loss: a nationwide, population-based cohort study. Otology & Neurotology. 2013;34(5):862-867. doi:10.1097/MAO.0b013e3182923fd5
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.